Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
- PMID: 37558706
- PMCID: PMC10412575
- DOI: 10.1038/s41408-023-00886-8
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
Abstract
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
© 2023. Springer Nature Limited.
Conflict of interest statement
CJF reports payment from participation on an advisory board from Sanofi, and currently holds equity in a publicly-traded company, Affimed. H.H. reports consultancy fees from Sanofi, Janssen, and Bristol Myers Squibb, and payment on speaker bureaus from Sanofi, GSK, and Karyopharm. JPM reports consultancy fees and honoraria from Magenta Therapeutics, Novartis, Bristol Myers Squibb, Juno Therapeutics, Kite, CRISPR Therapeutics, Nektar, and Allovir, reports honoraria from Sana, reports payment on speaker bureaus from Bristol Myers Squibb, Kite, and Allovir, and research funding from Magenta Therapeutics, Juno Therapeutics, Kite, Orca Bio, and Allovir. DWS reports consultancy fees from Sanofi, Bristol Myers Squibb, Janssen, AbbVie, GSK, and Pfizer, and membership on an entity’s Board of Directors or advisory committees for Janssen and GSK. CBW reports that her partner is currently employed at AbbVie. SA reports research funding from Janssen, GSK, and Amgen, honoraria from Sanofi, Takeda, Celgene, and GSK, membership on an entity’s Board of Directors or advisory committees for Janssen, and reports payment on speaker bureaus from Janssen, Sanofi, and GSK. PMV reports consultancy fees from Janssen, Karyopharm, Oncopeptides, AbbVie, Bristol Myers Squibb, Sanofi, GSK, and Pfizer, and involvement on a Data Safety and Monitoring committee for Sanofi. GK reports membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Cellectar, Sanofi, Janssen, and Arcellx. LDA reports honoraria and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb, Celgene, GSK, AbbVie, Pharmacyclics, Karyopharm, Janssen, Prothena, Sanofi, Beigene, and Amgen. GS reports speaker bureau payment from Kite/Gilead. LCP reports research funding from Bristol Myers Squibb. YL reports consultancy fees from Janssen, Juno, Vineti, Kite/Gilead, Novartis, Legend, Sorrento, Gamida Cell, Celgene, Bluebird Bio, and research funding from Janssen, Kite/Gilead, Merck, Celgene, Bluebird Bio, and Takeda. MJ reports consultancy fees, research funding, and membership on an entity’s Board of Directors or advisory committees from Janssen. ON reports membership on an entity’s Board of Directors or advisory committees from Bristol Myers Squibb, Karyopharm, GPCR Therapeutics, Adaptive Biotechnologies, GSK, and Janssen, and reports research funding from Takeda and Janssen. MA reports honoraria, payment on speaker bureaus, and membership on an entity’s Board of Directors or advisory committees for Bristol Myers Squibb and Janssen, and reports research funding from Bristol Myers Squibb. FLL reports consultancy fees from Takeda, Sana, Daiichi Sankyo, A2, Celgene, Wugen, Umoja, Novartis, Legend Biotech, Kite/Gilead, Janssen, Iovance, GammaDelta Therapeutics, Emerging Therapy Solutions Gerson Lehrman Group, EcoR1, Cowen, Calibr, Cellular Biomedicine Group, Bristol Myers Squibb, Celgene, Bluebird Bio, Allogene, and Amgen, reports research funding from Leukemia and Lymphoma Society, National Cancer Institute, CERo Therapeutics, Bristol Myers Squibb, Novartis, Kite/Gilead, Bluebird Bio, and Allogene, patents and royalties from several patents held by the institution in his name (unlicensed) in the field of cellular immunotherapy, and education or editorial activity from BioPharm Communications, ASH, Aptitude Health, CAREducation, Clinical Care Options Oncology, Imedex, and Society for Immunotherapy of Cancer. S.S. reports consultancy fees from Oncopeptides, Sanofi, Janssen, Magenta Therapeutics, and Bristol Myers Squibb, honoraria from Prothena, and research funding from Janssen, Magenta Therapeutics, Bristol Myers Squibb, and Allogene. DKH reports research funding and membership on an entity’s advisory committee from Bristol Myers Squibb, and reports honoraria from OncLive and Survivorship. KKP reports consultancy fees from Janssen, Celgene, Bristol Myers Squibb, Caribou Sciences, Arcellx, Cellectis, Merck, Pfizer, Karyopharm, and Oncopeptides. OACP reports payment on speaker bureaus from Adaptive Biotechnologies.
Figures
References
-
- GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma. 2022. https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dr....
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials